Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $102.00 Consensus PT from Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have earned an average rating of “Moderate Buy” from the fourteen brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, twelve have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $102.5833.

A number of equities analysts have recently commented on MIRM shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 target price on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. Citizens Jmp lifted their price objective on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the company a “market outperform” rating in a research note on Friday, December 19th. HC Wainwright reaffirmed a “buy” rating and issued a $102.00 target price (up from $81.00) on shares of Mirum Pharmaceuticals in a report on Tuesday, January 13th. Raymond James Financial reissued a “strong-buy” rating and set a $110.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. Finally, JMP Securities set a $95.00 price objective on Mirum Pharmaceuticals in a research note on Wednesday, November 5th.

Mirum Pharmaceuticals Stock Down 1.8%

Mirum Pharmaceuticals stock opened at $94.29 on Monday. The company has a market capitalization of $4.85 billion, a P/E ratio of -109.64 and a beta of 0.48. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. Mirum Pharmaceuticals has a fifty-two week low of $36.88 and a fifty-two week high of $96.84. The stock has a 50-day simple moving average of $77.33 and a 200-day simple moving average of $70.90.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The firm had revenue of $133.01 million for the quarter, compared to the consensus estimate of $130.11 million. During the same quarter last year, the business posted ($0.30) EPS. The firm’s quarterly revenue was up 47.1% compared to the same quarter last year. Equities research analysts expect that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Key Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Baird updated Mirum’s valuation after the company reported a beat-and-raise on results, a development that supports upside and follows recent analyst price-target increases. Baird updates Mirum valuation
• Positive Sentiment: Multiple brokerages have raised targets/ratings in recent weeks (Morgan Stanley, HC Wainwright, Stifel, Robert W. Baird and others), reflecting confidence in revenue growth and the company’s lead product (maralixibat). These upgrades help underpin higher consensus price targets. MarketBeat analyst notes
• Neutral Sentiment: Company fundamentals: Mirum is a late-stage biopharma focused on rare cholestatic liver diseases; recent quarter showed strong revenue growth and an EPS beat, but the company remains loss-making on GAAP metrics and carries leverage. This context supports analyst optimism but also ongoing execution risk. Company profile and results
• Neutral Sentiment: Institutional activity shows modest position changes by funds (small buys/sells), not a clear directional institutional shift. Institutional holdings
• Negative Sentiment: Significant insider selling: several senior executives sold shares on Jan. 22 — CEO Christopher Peetz (7,098 shares), COO Peter Radovich (2,382), CFO Eric Bjerkholt (1,421), SVP Jolanda Howe (926) and insider Joanne Quan (multiple recent sales). The block of insider sales (each at ~\$93.33) reduces insider ownership and is likely weighing on sentiment and the stock today. Insider trades alert

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 926 shares of the business’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total value of $86,423.58. Following the transaction, the senior vice president directly owned 3,042 shares of the company’s stock, valued at approximately $283,909.86. The trade was a 23.34% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Christopher Peetz sold 7,098 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total transaction of $662,456.34. Following the transaction, the chief executive officer owned 163,733 shares of the company’s stock, valued at approximately $15,281,200.89. The trade was a 4.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 20,560 shares of company stock valued at $1,897,717. Corporate insiders own 22.87% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MIRM. Eventide Asset Management LLC lifted its position in Mirum Pharmaceuticals by 4.4% in the second quarter. Eventide Asset Management LLC now owns 2,637,485 shares of the company’s stock valued at $134,224,000 after purchasing an additional 110,485 shares during the period. Geode Capital Management LLC raised its stake in shares of Mirum Pharmaceuticals by 6.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,029,616 shares of the company’s stock worth $52,405,000 after buying an additional 65,951 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Mirum Pharmaceuticals by 566.8% in the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock valued at $57,965,000 after buying an additional 672,118 shares during the period. Boone Capital Management LLC boosted its stake in shares of Mirum Pharmaceuticals by 6.3% in the second quarter. Boone Capital Management LLC now owns 641,448 shares of the company’s stock valued at $32,643,000 after buying an additional 38,130 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of Mirum Pharmaceuticals by 709.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock valued at $44,889,000 after buying an additional 536,674 shares in the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.